US bid to eliminate gene therapy panel under fire

Wadman, Meredith
June 1996
Nature;6/20/1996, Vol. 381 Issue 6584, p635
Academic Journal
Reports on growing opposition to a proposal by Harold Varmus, director of the US National Institutes of Health (NIH), to disband the agency's Recombinant DNA Advisory Committee (RAC). The committee's responsibility for reviewing and approving novel gene-therapy protocols; Varmus' wish to hand over this function to the US Food and Drug Administration (FDA).


Related Articles

  • A word to Varmus. Pryor, David; Hatfield, Mark // Hastings Center Report;Jul/Aug96, Vol. 26 Issue 4, p46 

    Presents a letter from legislators to National Institutes of Health director Harold Varmus expressing concerns for the proposed abolition of the Recombitant DNA Advisory Committee (RAC). Calls for reconsideration in disbanding the RAC; Policy issues on the RAC's role in genetics research.

  • Reversal on RAC.  // Hastings Center Report;Jan/Feb97, Vol. 27 Issue 1, p51 

    Reports on the withdrawal of a proposal to disband the National Institutes of Health's (NIH) Recombinant DNA Advisory Committee (RAC). Group's historical importance as a forum for discussion of the scientific and ethical aspects of gene therapy research; Reduction of the group's membership.

  • Recombinant DNA committee gets a reprieve. Baker, Beth // BioScience;Mar1997, Vol. 47 Issue 3, p139 

    Discusses the reason National Institutes of Health (NIH) Director Harold Varmus decided to allow the NIH's Recombinant DNA Advisory Committee (RAC) to continue. Varmus' original decision to do away with RAC; The criticism Varmus received for his original decision; The history of the organization.

  • Gene panel reprieved after public outcry... Wadman, Meredith // Nature;11/28/1996, Vol. 384 Issue 6607, p297 

    Discusses the announcement by Harold Varmus of a compromise on the future of the National Institutes of Health's (NIH) Recombinant DNA Advisory Committee (RAC). Varmus' role as director of the NIH; His original plan to abolish the RAC; The responsibilities being given to the US Food and Drug...

  • Recombinant DNA committee backs its proposed reform.  // Nature;12/12/1996, Vol. 384 Issue 6609, p506 

    Mentions that the National Institutes of Health's (NIH) Recombinant DNA Advisory Committee (RAC) approved a plan to overhaul itself. The plan from Harold Varmus, director of NIH; The controversy surrounding the status of the RAC.

  • Gene advisory group wrestles with its mission. Jenks, Susan // JNCI: Journal of the National Cancer Institute;7/5/95, Vol. 87 Issue 13, p959 

    Reports on the struggle of the National Institutes of Health's (NIH) Recombinant DNA Advisory Committee (RAC) with the underlying issue of whether to put safety or science first when reviewing proposed gene studies. Leanings of the RAC members toward safety during the June 1995 meeting; NIH...

  • In sickness and in health. Boyce, Nell // New Scientist;10/25/97, Vol. 156 Issue 2105, p20 

    Reports on the impact of gene therapy trials approved by the Recombinant DNA Advisory Committee of the US National Institutes of Health. Debate on the prevention of genetic engineering that changes normal characteristics; Effect of gene therapy on future generations; Risks of altering genetic...

  • Fears mount for gene scrutiny as watchdog faces axe. Kiernan, Vincent // New Scientist;6/08/96, Vol. 150 Issue 2033, p10 

    Reports on the proposed abolition of the US Recombinant DNA Advisory Committee (RAC) that was originally tasked to lay down guidelines for genetic engineering experiments in bacteria. Approval of human gene therapy trials; Transfer of RAC tasks to the Food and Drug Administration and review...

  • NIH review to suggest streamlined handling of gene therapy bids. Taylor, Robert // Nature;6/29/1995, Vol. 375 Issue 6534, p713 

    Reports on the conclusion made by an external advisory panel that the Recombinant DNA Advisory Committee (RAC) of the United States National Institutes of Health (NIH) need not review human gene therapy protocols similar to those already approved. Initial screening of applications to be made...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics